14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.59 $16.67 Thursday, 25th Apr 2024 CPRX stock ended at $14.68. This is 2.91% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 2.91% from a day low at $14.59 to a day high of $15.01.
90 days $13.12 $17.50
52 weeks $11.09 $17.77

Historical Catalyst Pharmaceuticals prices

Date Open High Low Close Volume
Mar 20, 2024 $16.30 $16.93 $16.26 $16.91 893 767
Mar 19, 2024 $16.05 $16.42 $15.85 $16.39 875 137
Mar 18, 2024 $16.04 $16.39 $15.75 $16.08 1 065 185
Mar 15, 2024 $16.10 $16.35 $15.98 $16.07 2 974 678
Mar 14, 2024 $17.02 $17.02 $16.04 $16.19 1 291 721
Mar 13, 2024 $16.44 $16.95 $16.35 $16.62 1 356 303
Mar 12, 2024 $16.24 $16.35 $16.10 $16.20 859 442
Mar 11, 2024 $16.24 $16.41 $16.06 $16.10 856 025
Mar 08, 2024 $16.92 $17.04 $16.18 $16.25 1 029 005
Mar 07, 2024 $16.29 $16.75 $16.07 $16.64 1 055 181
Mar 06, 2024 $16.41 $16.50 $15.75 $15.86 977 239
Mar 05, 2024 $16.70 $16.80 $16.03 $16.27 1 128 209
Mar 04, 2024 $17.23 $17.39 $16.56 $16.69 1 523 381
Mar 01, 2024 $16.21 $17.50 $16.18 $17.01 3 625 536
Feb 29, 2024 $16.29 $16.50 $15.29 $16.03 4 151 223
Feb 28, 2024 $14.27 $14.73 $14.17 $14.56 1 691 869
Feb 27, 2024 $14.21 $14.40 $14.16 $14.35 1 215 123
Feb 26, 2024 $14.04 $14.29 $13.92 $14.18 1 069 800
Feb 23, 2024 $13.91 $14.15 $13.70 $14.04 682 225
Feb 22, 2024 $13.77 $14.02 $13.49 $13.90 1 133 501
Feb 21, 2024 $13.77 $13.90 $13.57 $13.71 739 435
Feb 20, 2024 $14.00 $14.35 $13.66 $13.79 1 303 067
Feb 16, 2024 $13.86 $14.09 $13.71 $14.00 985 088
Feb 15, 2024 $13.56 $13.96 $13.56 $13.89 971 333
Feb 14, 2024 $13.34 $13.53 $13.28 $13.48 908 869
Click to get the best stock tips daily for free!

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop... CPRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT